FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Co ...

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Just when the ladies of “Real Housewives of Orange County” attempt to make peace with each other, walking grenade Alexis ...

Research has shown that journaling can enhance memory and uplift mood. Consistent diary writing has also been linked to ...

Mental flexibility – rather than mental toughness – is the key to maximising running performance and enjoyment.

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...

Juan Karlos 'JK' Labajo’s music is like a love letter—raw, unapologetic, and deeply personal. Each melody and lyric sounds ...

Vivos Therapeutics, Inc. ( NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Kirk Huntsman - Chariman & CEO Brad Amman - CFO Scott Henry - Alliance Global Partners Lucas Ward ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14 ...